Hemophilia Research Today is a free monthly online journal that collates and summarizes the latest research about Hemophilia, including details on genetics, causes, symptoms, blood transfusion.

Immune response against therapeutic factor VIII in hemophilia A patients--a survey of probable risk factors.

Dasgupta S, Navarrete AM, Delignat S, Wootla B, Andre S, Nagaraja V, Lacroix-Desmazes S, Kaveri SV

INSERM, UMR S 872, Les Cordeliers, Paris F-75006, France.

A number of diseases are treated by passive administration of human proteins. Human coagulation factor VIII (FVIII) is one such protein which is administered to hemophilia A patients in order to manage and treat hemorrhagic incidences. This mode of therapy suffers from the side effect of generating anti-FVIII antibodies (inhibitors) which neutralizes the function of the infused FVIII. At a time when efficient viral screening procedures are at place, development of inhibitors poses the greatest threat to such a therapy. Various predisposing factors, both patient and product-related, are responsible for the development of inhibitory antibodies. A proper understanding of these "risk-factors" would eventually help to better design therapeutic regimen to tackle hemophilia A.

Published 8 May 2007 in Immunol Lett, 110(1): 23-8.
Full-text of this article is available online (may require subscription).

© 2005-2008 Hemophilia Research Today. All Rights Reserved.